TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03319823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiazide Treatment Group
Description: Thiazide Treatment Group: Non-diabetics with sleep systolic blood pressure of 125-139 mm Hg and awake systolic blood pressure \<160 mm Hg Participants will be treated with Indapamide 0.625mg once a day After 4 weeks of treatment, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring the investigators will repeat ambulatory blood pressure monitoring at 4, 8, and 12 weeks after treatment initiation.~If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensified Thiazide Treatment Group
Description: At 4 weeks of therapy, individuals initially assigned to the Thiazide treatment group whose ambulatory blood pressure recheck showed a sleep systolic blood pressure \>120 mm Hg, the investigators will intensify their blood pressure medications by adding on Telmisartan 40 mg and Amlodipine 5 mg. In two week intervals, labs and ambulatory blood pressure will be measured. If the systolic blood pressure \>120, then the doses of Telmisartan and Amlodipine will be up-titrated until the sleep systolic blood pressure is \<120.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Medication Treatment Group
Description: Combination Medication Treatment Group: Diabetics or sleep systolic blood pressure of ≥ 140 mm Hg, or awake systolic blood pressure of ≥ 160 mm Hg~* Participants will be treated with starting doses of a long acting blood pressure regimen of Telmisartan 40 mg and Amlodipine 5 mg daily~* After 2 weeks, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring~  * If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment and repeat ambulatory blood pressure again in another 2 weeks to assess reproducibility~ * If sleep systolic blood pressure is \> 120 mm Hg, the investigators will increase Telmisartan dose to 80 mg and the Amlodipine dose to 10 mg. Ambulatory blood pressure monitoring will be checked again after 2 weeks of therapy to verify efficacy.
Study: NCT01435486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate
Description: Single stat dose (25 mg per kilogram of body weight) of intravenous caffeine citrate (25mg caffeine citrate equal to 12.5mg caffeine base).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo with an equivalent volume of normal saline.
Study: NCT04265417

Intervention type: PROCEDURE
Intervention: Robotic Assisted Rectal Cancer Resection Alone
Description: participants in this group underwent robotic assisted rectal cancer resection alone, the specimens were extracted through the incision on the abdominal wall.
Study: NCT01763606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Patients will be receive 6 months of subcutaneous enoxaparin (1 mg/kg BID with a maximum starting dose of 100 mg BID. Patients who weigh more than 100 kg will start at a dose of 100 mg BID; their subsequent dosing will be guided by hematology and may change.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Patients will receive 6 months of oral aspirin (81 mg per day unless a higher dose is preferred by study physicians although the maximum acceptable dose will be 325 mg per day).
Study: NCT02449161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02451020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude exposure
Description: Participants will stay for 3 weeks at an altitude of 3200 m
Study: NCT01959841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: 200 mg once daily or 400 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: 200 mg once daily or 400 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valaciclovir
Description: 1000 mg three times daily
Study: NCT02005588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amino acid chelated iron
Description: the drug will be given to pregnant women 14-18 weeks' gestation who prove to have iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily. for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amino acid chelated iron
Description: the drug will be given to pregnant women 14-18 weeks' gestation who prove to have iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily. for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron salt (ferrous fumarate)
Description: this drug will be given to pregnant women 14-18 weeks' gestation with iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily, and for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron salt (ferrous fumarate)
Description: this drug will be given to pregnant women 14-18 weeks' gestation with iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily, and for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
Study: NCT01400568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPS challenge with nebulized LPS
Description: 20,000 EU of Clinical Center Reference Endotoxine (CCRE) will be applied by an AKITA® Jet Nebulizer under the constant supervision of the site staff.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate (FP)
Description: The dosage of FP will be 2 mg. This dosage will be inhaled by 4 puffs of Flutide® forte 500 Diskus® 500 µg / dose according to the package insert.
Study: NCT02016079

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3
Description: 200 ml fruit drink containing omega-3
Study: NCT03113994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin Calcium
Description: 10mg Rosuvastatin, daily for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo, daily for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Coenzyme Q10
Description: 100mg CoQ10, daily for 12 months
Study: NCT04265417

Intervention type: PROCEDURE
Intervention: Robotic Assisted Rectal Cancer Resection With Natural Orifice Specimen Extraction
Description: participants in this group underwent robotic rectal cancer resection，the specimens were extractd through anus and vagina.
Study: NCT00022399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: 400mg PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
Study: NCT03113994

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: 100mg CoQ10, daily for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate
Description: 1250mg Calcium Carbonate, daily for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: 1250mg Calcium Carbonate, daily for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: 2000IU Vitamin D, daily for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 2000IU Vitamin D, daily for 12 months
Study: NCT02934724

Intervention type: PROCEDURE
Intervention: Self sample from vagina
Description: Self sample using The Rover's Evalyn Brush

Intervention type: PROCEDURE
Intervention: Self sample from vagina
Description: Self sample using The Rover's Evalyn Brush

Intervention type: PROCEDURE
Intervention: Self sample from the oral cavity
Description: Self sample using COPAN FloqSwab

Intervention type: PROCEDURE
Intervention: Self sample from the oral cavity
Description: Self sample using COPAN FloqSwab

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire about vaccination status and sexual behaviour

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire about vaccination status and sexual behaviour
Study: NCT00544076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT03495882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1884 + AGEN2034
Description: AGEN1884 + AGEN2034 according to protocol design
Study: NCT00400647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated Mycophenolate sodium (EC-MPS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Study: NCT03802448

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Study group
Description: Each pregnant woman in the study group received myofascial release technique, 3 sessions/week for 4 weeks. a myofascial release in addition to wearing a natural wrist splint during sleeping for 4 weeks.~Myofascial wrist retinaculum (Transverse carpal ligament) release.~• Second part; Interosseous membrane and forearm muscles myofascial release (Bilateral thumb pressure technique).
Study: NCT00421928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Description: 10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo twice a day (BID) during 15 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503)
Description: 50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks
Study: NCT01024894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-7
Description: 3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week
Study: NCT03802448

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control group
Description: A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping.
Study: NCT00437684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: 200/50 mg 2 cpr bid monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LPV/r
Description: 200/50 mg 2 cpr bid monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFNa 2a
Description: PEG-IFNa 2a 180 mcg/week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-IFNa 2a
Description: PEG-IFNa 2a 180 mcg/week
Study: NCT01602822

Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir, Atazanavir, Truvada
Study: NCT02205463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD019
Study: NCT02368964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist 0.2 mg + hCG 250 mcg
Description: Treatment for triggering

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose hCG 500 mcg
Description: Treatment for triggering
Study: NCT00437684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 1-1.2 g/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin 1-1.2 g/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NUCS
Description: Nucleoside Reverse Transcriptase Inhibitors
Study: NCT01537783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Scrubs applied once a day for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Description: Nasal mupirocin applied topically to both nostrils twice a day for 5 days
Study: NCT01408186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: Rabeprazole 20 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Famotidine 40mg daily
Study: NCT02888327

Intervention type: DRUG
Group type: OTHER
Intervention: AL-794

Intervention type: DRUG
Group type: OTHER
Intervention: AL-794

Intervention type: DRUG
Group type: OTHER
Intervention: AL-794

Intervention type: DRUG
Group type: OTHER
Intervention: AL-794

Intervention type: DRUG
Group type: OTHER
Intervention: Oseltamivir

Intervention type: DRUG
Group type: OTHER
Intervention: Digoxin

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam

Intervention type: DRUG
Group type: OTHER
Intervention: Pitavastatin

Intervention type: DRUG
Group type: OTHER
Intervention: JNJ-63623872
Study: NCT03578744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Flap surgery
Description: After administering local anaesthetic a full thickness flap will be raised and reflected to expose the furcation defects. The furcation defects would then be debrided and the graft and membrane secured in position. Later the flap would be sutured back.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Flap surgery
Description: After administering local anaesthetic a full thickness flap will be raised and reflected to expose the furcation defects. The furcation defects would then be debrided and the graft and membrane secured in position. Later the flap would be sutured back.
Study: NCT03241641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: 25mg, Daily Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Alafenamide
Description: 25mg, Daily Oral
Study: NCT01701089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-L-deprenyl-D2
Description: Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-L-deprenyl-D2
Description: Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total
Study: NCT03241641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: 300mg, Daily Oral
Study: NCT03782168

Intervention type: OTHER
Intervention: There is no other intervention, only clinical treatment.
Description: The purpose of this study is to determine how well maternal serum biomarkers and placental micro-particles (MP) correlate with PA. The sensitivity and specificity of these proteins will be analyzed to further increase our understanding of the pathological mechanisms involved in PA.

Intervention type: OTHER
Intervention: There is no other intervention, only clinical treatment.
Description: The purpose of this study is to determine how well maternal serum biomarkers and placental micro-particles (MP) correlate with PA. The sensitivity and specificity of these proteins will be analyzed to further increase our understanding of the pathological mechanisms involved in PA.
Study: NCT01753180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagenase
Description: Local intra-coronary administration of MZ-004 at or into the CTO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Local intra-coronary administration of saline at or into the CTO
Study: NCT02754050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem Snare
Study: NCT00451204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estriol
Description: Estriol 8 mg capsule, once per day, duration of treatment is 2 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, once a day, treatment duration is 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copaxone
Description: Injection, once a day, all subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Copaxone
Description: Injection, once a day, all subjects
Study: NCT03923140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: 5mg/kg.d for juvenile patients with a maximum dose of 0.3g per day; 0.1g each time, three times a day for adults patients
Study: NCT01480869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium and cholecalciferol
Description: Tablet to suck: calcium 500 mg bid, cholecalciferol 200 IU bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium and cholecalciferol
Description: Tablet: calcium 500 mg bid + 2 ml drinkable solution cholecalciferol 100 000 IU whose schedule of administration depends on vitamin deficiency level:~* 100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25-OHD level \< 10 ng/mL~* 100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25-OHD level \< 20 ng/mL~* 100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25-OHD level \< 30 ng/mL
Study: NCT01184495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa-BioManguinhos
Description: Subcutaneous administration of EPO-BioManguinhos
Study: NCT02874469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diary
Description: The diary was specifically created for the purpose of the present study by personal working at ICU at CHRU of Lille (France).~All relatives, doctors and paramedics close to the patient during his hospital stay are allowed to write some comments inside the diary when he is comatose.~The diary will be implemented during the second period of the study within the first 8 hours after admission.~It will be given to the patients themselves at discharge or to their relatives in case of in-hospital death. An anonymous copy will be kept by investigators.
Study: NCT01184495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa-BioSimilar
Description: Subcutaneous administration of EPO-BioSimilar
Study: NCT01701089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4602522
Description: Multiple doses of RO4602522 for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4602522
Description: Multiple doses of RO4602522 for up to 17 days
Study: NCT04054245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXL2 Inhibitor PAT-1251
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00396409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depigoid
Description: Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depigoid
Description: Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: anti-IgE (Omalizumab) given during the 2006 core study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given during the 2006 core study
Study: NCT05971615

Intervention type: OTHER
Group type: OTHER
Intervention: peripheral venous blood gases
Description: peripheral venous blood gases
Study: NCT01878955

Intervention type: GENETIC
Intervention: AMH level difference between patient with PCOS and multicystic ovaries.
Study: NCT02854709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension
Description: Sleep extension by 1 hour for 2 weeks
Study: NCT04564222

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Enriched Crackers (MECs)
Description: MECs are manufactured according to the Standard Operational Procedures which have been developed taking into account the Hazard Analysis and Critical Control Point (HACCP) to maintain quality and safety and ensure the Ready-to-eat MEC products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detectable) in the MEC products have been obtained from analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of MEC products will be repeated at the middle and the end of the RCT to check on the quality and safety of the MEC product.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo crackers are manufactured according to SOPs which have been developed taking into account the HACCP to maintain quality and safety and ensure the Ready-to-eat placebo products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detected) in the placebo have been obtained based on the analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of placebo samples will be repeated at the middle and the end of the RCT to check on the quality and safety of the placebo product.
Study: NCT03131271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold application
Description: In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter.
Study: NCT04898686

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic chewables
Description: chewables containing Lacticaseibacillus rhamnosus GG

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo chewables
Description: chewables without probiotic strain. Ingredients: Xylitol, microcrystalline cellulose, stearic acid, natural orange flavor, silica, magnesium stearate, citric acid and malic acid.